GLP-1受体激活剂和糖尿病病:在现场的游戏充电器?
Georgia Doumani1, Panagiotis Theofilis1, Vasilis Tsimihodimos2
1General Hospital of Nikaia-Piraeus Agios Panteleimon, Center for Nephrology "G. Papadakis", 18454 Piraeus, Greece.
Life (Basel, Switzerland)
|November 27, 2024
概括
2型糖尿病 (T2DM) 显著导致慢性病 (CKD). 类似葡萄糖类-1受体激动剂 (GLP-1RAs),像塞马格卢提德一样,在提高高危患者的脏,心血管和生存结果方面表现有前途.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
背景情况:
- 慢性病 (CKD) 是一种全球性流行病,其主要驱动因素是2型糖尿病 (T2DM).
- 与T2DM相关的CKD显著增加了心血管事件,末期病 (ESKD),发病率和死亡率的风险.
- 目前的治疗策略,包括氨酸- ангиотензин- алдостерон系统阻断剂和SGLT2抑制剂,在控制CKD进展方面取得了部分成功.
研究的目的:
- 评估新型治疗途径在减缓T2DM患者中CKD进展中的作用.
- 评估类似葡萄糖-1受体激动剂 (GLP-1RAs) 作为T2DM相关病的转化治疗的潜力.
- 分析FLOW试验中关于塞马格卢提德对脏,心血管和生存结果的影响的发现.
主要方法:
- 对T2DM相关的CKD治疗干预措施的现有文献的审查.
- 对临床试验数据的分析,包括最近的FLOW试验.
- 在高风险患者群体中评估GLP-1RA的疗效和安全性.
主要成果:
- -葡萄糖共运输体2抑制剂和芬瑞在降低糖尿病患者中CKD进展和心血管事件方面已经证明有效.
- FLOW试验证实,在患有CKD的高风险T2DM患者中,塞马格卢提德提供了显著的脏,心血管和生存益处.
- GLP-1RA正在成为一种关键的治疗选择,可能会改变与T2DM相关的脏疾病的管理环境.
结论:
- 尽管有进展,但新的治疗策略对于管理T2DM相关的CKD进展和相关死亡率至关重要.
- 通过赛马格卢提德示例的GLP-1RAs代表了显著的治疗进步,证明了对脏,心血管和生存结果的好处.
- 进一步的大规模研究是有必要的,以充分阐明GLP-1RAs的风险概况,以及它们日益增长的临床应用.
相关概念视频
Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
Oral Hypoglycemic Agents: Glinides
141
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
141
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K


